Business Description
Akero Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US00973Y1082
Description
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 20.96 | |||||
| Equity-to-Asset | 0.92 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | -0.18 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -3.5 | |||||
| 3-Year EPS without NRI Growth Rate | -4.7 | |||||
| 3-Year FCF Growth Rate | -7 | |||||
| 3-Year Book Growth Rate | 8.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -9.39 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 58.18 | |||||
| 9-Day RSI | 57.8 | |||||
| 14-Day RSI | 57.75 | |||||
| 6-1 Month Momentum % | 44.24 | |||||
| 12-1 Month Momentum % | 140.69 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 24.89 | |||||
| Quick Ratio | 24.89 | |||||
| Cash Ratio | 24.39 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -17.1 | |||||
| Shareholder Yield % | -17.26 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -30.21 | |||||
| ROA % | -27.92 | |||||
| ROIC % | -564.17 | |||||
| 3-Year ROIIC % | -479.3 | |||||
| ROC (Joel Greenblatt) % | -19513.45 | |||||
| ROCE % | -28.38 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.67 | |||||
| Price-to-Tangible-Book | 2.68 | |||||
| EV-to-EBIT | -7.04 | |||||
| EV-to-Forward-EBIT | -4.93 | |||||
| EV-to-EBITDA | -7.04 | |||||
| EV-to-Forward-EBITDA | -5.03 | |||||
| EV-to-FCF | -7.38 | |||||
| Price-to-Net-Current-Asset-Value | 3.01 | |||||
| Price-to-Net-Cash | 3.08 | |||||
| Earnings Yield (Greenblatt) % | -14.2 | |||||
| FCF Yield % | -8.92 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AKRO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Akero Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -3.44 | ||
| Beta | -0.9 | ||
| Volatility % | 109.42 | ||
| 14-Day RSI | 57.75 | ||
| 14-Day ATR ($) | 1.445251 | ||
| 20-Day SMA ($) | 29.5225 | ||
| 12-1 Month Momentum % | 140.69 | ||
| 52-Week Range ($) | 12.96 - 37 | ||
| Shares Outstanding (Mil) | 69.43 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Akero Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Akero Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Akero Therapeutics Inc Frequently Asked Questions
What is Akero Therapeutics Inc(AKRO)'s stock price today?
The current price of AKRO is $30.87. The 52 week high of AKRO is $37.00 and 52 week low is $12.96.
When is next earnings date of Akero Therapeutics Inc(AKRO)?
The next earnings date of Akero Therapeutics Inc(AKRO) is 2024-11-13 Est..
Does Akero Therapeutics Inc(AKRO) pay dividends? If so, how much?
Akero Therapeutics Inc(AKRO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers